{"changes":[],"country":"FR","description":"STEP Pharma develops dencatistat (STP938), a first-in-class oral CTPS1 inhibitor designed to treat T-cell lymphomas, B-cell lymphomas, solid tumors, and essential thrombocythaemia. It targets oncology patients in cancers where survival has stagnated for decades, especially peripheral T-cell lymphoma. Most advanced selective CTPS1 inhibitor in clinical development.","domain":"step-ph.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":46.243244,"lng":6.020778,"location":"Saint-Genis-Pouilly, France","name":"STEP Pharma","rounds":[{"amountQuarantined":false,"amountUsd":2700000,"currency":"EUR","date":"2026-04-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"step-ph-com","sources":[{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"step-ph.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://step-ph.com"},{"fact":"description","publisher":"step-ph.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://step-ph.com"}],"stage":null,"techStack":["Nginx","WordPress 7.0","Yoast SEO 27.6","Slider Revolution","jQuery Migrate 3.4.1","imagesLoaded 5.0.0","PHP","MySQL","jquery 3."],"totalRaisedUsd":2700000,"updatedAt":"2026-05-08"}